Nls pharmaceutics highlights innovative preclinical program for first-in-class non-sulfonamide dual orexin receptor agonists (doxa) in narcolepsy and neurological disorders

ZÜrich, switzerland / accesswire / november 18, 2024 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, provided insights today into the preclinical program evaluating its dual orexin receptor agonist (doxa) platform.
NLSP Ratings Summary
NLSP Quant Ranking